Progesterone and related compounds in hepatocellular carcinoma: Basic and clinical aspects

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Yeh, Yao Tsung ^a   Chang, Chien Wei ^a,b   Wei, Ren Jie ^a,c   Wang, Shen Nien ^b,d  

^a FOOYIN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; MEGESTROL ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MEDROXYPROGESTERONE ACETATE;

AMINO TERMINAL SEQUENCE; BINDING SITE; CANCER PROGNOSIS; CANCER SURVIVAL; DIMERIZATION; DNA BINDING; ENZYME ACTIVATION; HORMONE ACTION; HORMONE BINDING; HORMONE RESPONSIVE ELEMENT; HUMAN; LIGAND BINDING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; FEMALE; LIVER NEOPLASMS; MALE; METABOLISM; MORTALITY; PATHOLOGY; SEXUAL DEVELOPMENT; CHEMICALLY INDUCED DISORDER; LIVER TUMOR;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; ESTROGENS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; SEX CHARACTERISTICS;

EID: 84874636053     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/290575     Document Type: Review

References (106)

1. Parkin D. M., Global cancer statistics in the year 2000. Lancet Oncology 2001 2 9 533 543 2-s2.0-0035467993 10.1016/S1470-2045(01)00486-7 (Pubitemid 33586866)
2. El-Serag H. B., Rudolph K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557 2576 2-s2.0-34250020201 10.1053/j.gastro.2007.04.061 (Pubitemid 46890874)
3. El-Serag H. B., Hepatocellular carcinoma. New England Journal of Medicine 2011 365 12 1118 1127
4. El-Serag H. B., Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease 2001 5 1 87 107 2-s2.0-0035140369 (Pubitemid 32118640)
5. Mucci L. A., Kuper H. E., Tamimi R., Lagiou P., Spanos E., Trichopoulos D., Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. British Journal of Obstetrics and Gynaecology 2001 108 3 291 294 2-s2.0-0035098117 10.1016/S0306-5456(00)00032-2 (Pubitemid 32210130)
6. El-Serag H. B., Hepatocellular carcinoma: an epidemiologic view. Journal of Clinical Gastroenterology 2002 35 5, supplement 2 S72 S78 2-s2.0-0036841697 10.1097/00004836-200211002-00002 (Pubitemid 35278644)
7. Erdstein J., Wisebord S., Mishkin S. Y., Mishkin S., The effect of several sex steroid hormones on the growth rate of three morris hepatoma tumor lines. Hepatology 1989 9 4 621 624 2-s2.0-0024537376 (Pubitemid 19094588)
8. Yeh S. H., Chen P. J., Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010 78 1 172 179 2-s2.0-77954478949 10.1159/000315247
9. Mulvihill J. J., Ridolfi R. L., Schultz F. R., Hepatic adenoma in Fanconi anemia treated with oxymetholone. Journal of Pediatrics 1975 87 1 122 124 2-s2.0-0016769429
10. Meadows A. T., Naiman J. L., Valdes Dapena M., Hepatoma associated with androgen therapy for aplastic anemia. Journal of Pediatrics 1974 84 1 109 110 2-s2.0-0015973976
11. Shimizu I., Yasuda M., Mizobuchi Y., Ma Y. R., Liu F., Shiba M., Horie T., Ito S., Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut 1998 42 1 112 119 2-s2.0-0031960462 (Pubitemid 28228398)
12. Yu M. W., Chang H. C., Chang S. C., Liaw Y. F., Lin S. M., Liu C. J., Lee S. D., Lin C. L., Chen P. J., Lin S. C., Chen C. J., Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003 38 6 1393 1400 2-s2.0-0344155206 10.1016/j.hep.2003.09.041 (Pubitemid 37466965)
13. Shimizu I., Impact of oestrogens on the progression of liver disease. Liver International 2003 23 1 63 69 2-s2.0-0038207707 (Pubitemid 37265776)
14. Codes L., Asselah T., Cazals-Hatem D., Tubach F., Vidaud D., Paraná R., Bedossa P., Valla D., Marcellin P., Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007 56 3 390 395 2-s2.0-34047138812 10.1136/gut.2006.101931 (Pubitemid 46579771)
15. Simonetti R. G., Camma C., Fiorello F., Politi F., D'Amico G., Pagliaro L., Hepatocellular carcinoma. A worldwide problem and the major risk factors. Digestive Diseases and Sciences 1991 36 7 962 972 2-s2.0-0025835071
16. Fattovich G., Stroffolini T., Zagni I., Donato F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 S35 S50 2-s2.0-7044272630 10.1053/j.gastro.2004.09.014 (Pubitemid 39423368)
17. Guechot J., Peigney N., Ballet F., Vaubourdolle M., Giboudeau J., Poupon R., Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer 1988 62 4 760 762 2-s2.0-0023713385
18. Farinati F., De Maria N., Marafin C., Fagiuoli S., Libera G. D., Naccarato R., Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor. European Journal of Gastroenterology and Hepatology 1995 7 2 145 150 2-s2.0-0028831249
19. Weigel N. L., Moore N. L., Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Molecular Endocrinology 2007 21 10 2311 2319 2-s2.0-34948900221 10.1210/me.2007-0101 (Pubitemid 47529347)
20. Stanisić V., Lonard D. M., O'Malley B. W., Modulation of steroid hormone receptor activity. Progress in Brain Research 2010 181 153 176 2-s2.0-77955500692
21. Migliaccio A., Castoria G., Auricchio F., Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. International Journal of Biochemistry and Cell Biology 2007 39 7-8 1343 1348 2-s2.0-34447094278 10.1016/j.biocel.2006.12.009 (Pubitemid 47031025)
22. Ma W. L., Hsu C. L., Yeh C. C., Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012 56 1 176 185
23. Nagasue N., Kohno H., Chang Y. C., Yamanoi A., Nakamura T., Yukaya H., Hayashi T., Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas. Annals of Surgery 1990 212 2 150 154 2-s2.0-0025369255 (Pubitemid 20241039)
24. Nagasue N., Kohno H., Yamanoi A., Kimoto T., Chang Y. C., Nakamura T., Progesterone receptor in hepatocellular carcinoma: correlation with androgen and estrogen receptors. Cancer 1991 67 10 2501 2505 2-s2.0-0025873314
25. Mandlekar S., Kong A. N. T., Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001 6 6 469 477 2-s2.0-0035181465 10.1023/A:1012437607881 (Pubitemid 33078758)
26. Guo R., Wang T., Shen H., Ge H. M., Sun J., Huang Z. H., Shu Y. Q., Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2. Biomedicine and Pharmacotherapy 2010 64 4 249 253 2-s2.0-77952296186 10.1016/j.biopha.2009.06.007
27. Villa E., Dugani A., Fantoni E., Camellini L., Buttafoco P., Grottola A., Pompei G., De Santis M., Ferrari A., Manenti F., Type of estrogen receptor determines response to antiestrogen therapy. Cancer Research 1996 56 17 3883 3885 2-s2.0-9444267705 (Pubitemid 26284732)
28. Gelmann E. P., Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Seminars in Oncology 1997 24 1, supplement S1 S1 2-s2.0-0031052651
29. Chow P. K. H., Tai B. C., Tan C. K., Machin D., Win K. M., Johnson P. J., Soo K. C., High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002 36 5 1221 1226 2-s2.0-0036830308 10.1053/jhep.2002.36824 (Pubitemid 35253439)
30. Villa E., Colantoni A., Grottola A., Ferretti I., Buttafoco P., Bertani H., De Maria N., Manenti F., Variant estrogen receptors and their role in liver disease. Molecular and Cellular Endocrinology 2002 193 1-2 65 69 2-s2.0-0037205923 10.1016/S0303-7207(02)00097-7 (Pubitemid 34823608)
31. Boonyaratanakornkit V., McGowan E., Sherman L., Mancini M. A., Cheskis B. J., Edwards D. P., The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Molecular Endocrinology 2007 21 2 359 375 2-s2.0-33846581488 10.1210/me.2006-0337 (Pubitemid 46184890)
32. Villa E., Ferretti I., Grottola A., Buttafoco P., Buono M. G., Giannini F., Manno M., Bertani H., Dugani A., Manenti F., Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. British Journal of Cancer 2001 84 7 881 885 2-s2.0-17744383359 10.1054/bjoc.2000.1534 (Pubitemid 32385828)
33. Zhang K., Chow P. K. H., The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clinical Cancer Research 2004 10 15 5226 5232 2-s2.0-4143068028 10.1158/1078-0432.CCR-04-0061 (Pubitemid 39099797)
34. Di Maio M., Daniele B., Pignata S., Gallo C., De Maio E., Morabito A., Piccirillo M. C., Perrone F., Is human hepatocellular carcinoma a hormone-responsive tumor? World Journal of Gastroenterology 2008 14 11 1682 1689 2-s2.0-41849114144 10.3748/wjg.14.1682 (Pubitemid 351493374)
35. Chao Y., Chan W. K., Wang S. S., Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 1997 12 4 277 281 (Pubitemid 27244517)
36. Chow P. K., Machin D., Chen Y., Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. British Journal of Cancer 2011 105 7 945 952
37. Fu X. D., Giretti M. S., Baldacci C., Garibaldi S., Flamini M., Sanchez A. M., Gadducci A., Genazzani A. R., Simoncini T., Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 2008 3 7 2-s2.0-51349152827 10.1371/journal.pone. 0002790 e2790
38. Zeze F., Onami S., Osato K., Experimental studies on endocrine therapy for rat hepatocellular carcinoma. Nippon Geka Gakkai Zasshi 1995 96 11 760 765 2-s2.0-0029396438
39. Wang S. N., Yeh Y. T., Yang S. F., Potential role of leptin expression in hepatocellular carcinoma. Journal of Clinical Pathology 2006 59 9 930 934
40. Uchino J., Une Y., Sato Y., Gondo H., Nakajima Y., Sato N., Chemohormonal therapy of unresectable hepatocellular carcinoma. American Journal of Clinical Oncology 1993 16 3 206 209 2-s2.0-0027229395 (Pubitemid 23184382)
41. Aufrere M. B., Benson H., Progesterone: an overview and recent advances. Journal of Pharmaceutical Sciences 1976 65 6 783 800 2-s2.0-0017082318
42. Chakmakjian Z. H., Zachariag N. Y., Bioavailability of progesterone with different modes of administration. Journal of Reproductive Medicine for the Obstetrician and Gynecologist 1987 32 6 443 448 2-s2.0-0023245408 (Pubitemid 17106707)
43. Adlercreutz H., Martin F., Biliary excretion and intestinal metabolism of progesterone and estrogens in man. Journal of Steroid Biochemistry 1980 13 2 231 244 2-s2.0-0019189266 10.1016/0022-4731(80)90196-X (Pubitemid 10079039)
44. Whitehead M. I., Townsend P. T., Gill D. K., Absorption and metabolism of oral progesterone. British Medical Journal 1980 280 6217 825 827 2-s2.0-0018907169 (Pubitemid 10147114)
45. Wiswell J. G., Samuels L. T., The metabolism of progesterone by liver tissue in vitro. The Journal of Biological Chemistry 1953 201 1 155 160 2-s2.0-77049146155
46. Atherden L. M., Progesterone metabolism; investigation of the products of metabolism with human liver in vitro. The Biochemical Journal 1959 71 2 411 415 2-s2.0-24344482787
47. Berliner D. L., Wiest W. G., The extra-hepatic metabolism of progesterone in rats. The Journal of Biological Chemistry 1956 221 1 449 459 2-s2.0-33751109696
48. Wiest W. G., The metabolism of progesterone to delta4-pregnen-20alpha-ol- 3-one in eviscerated female rats. The Journal of Biological Chemistry 1956 221 1 461 467 2-s2.0-33751081496
49. Wiebe J. P., Progesterone metabolites in breast cancer. Endocrine-Related Cancer 2006 13 3 717 738 2-s2.0-33751120714 10.1677/erc.1.01010 (Pubitemid 44763254)
50. Sasagawa S., Shimizu Y., Kami H., Takeuchi T., Mita S., Imada K., Kato S., Mizuguchi K., Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008 73 2 222 231 2-s2.0-37649011457 10.1016/j.steroids.2007.10.003
51. Kemppainen J. A., Langley E., Wong C. I., Bobseine K., Kelce W. R., Wilson E. M., Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Molecular Endocrinology 1999 13 3 440 454 2-s2.0-0032935119 (Pubitemid 29113876)
52. Kuhl H., Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005 8 1, supplement 3 63 2-s2.0-24144485432 10.1080/13697130500148875 (Pubitemid 41232429)
53. Mueck A. O., Sitruk-Ware R., Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011 76 6 531 539 2-s2.0-79954587977 10.1016/j.steroids.2011.02.002
54. Africander D., Verhoog N., Hapgood J. P., Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011 76 7 636 652 2-s2.0-79956289710 10.1016/j.steroids.2011.03.001
55. Dinny Graham J., Clarke C. L., Physiological action of progesterone in target tissues. Endocrine Reviews 1997 18 4 502 519 2-s2.0-8544252436 10.1210/er.18.4.502 (Pubitemid 27349554)
56. Cooke B. A., Vallance D. K., Metabolism of megestrol acetate and related progesterone analogues by liver preparations in vitro. Biochemical Journal 1965 97 3 672 677 2-s2.0-0013835636
57. Teulings F. A. G., Van Gilse H. A., Henkelman M. S., Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Research 1980 40 7 2557 2561 2-s2.0-0018854496 (Pubitemid 10082284)
58. López A. P., Roqué I Figuls M., Cuchi G. U., Berenstein E. G., Pasies B. A., Alegre M. B., Herdman M., Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management 2004 27 4 360 369 2-s2.0-1642634608 10.1016/j.jpainsymman. 2003.09.007 (Pubitemid 38410904)
59. Langdon S. P., Gabra H., Bartlett J. M. S., Rabiaz G. J., Hawkins R. A., Tesdale A. L., Ritchie A. A., Miller W. R., Smyth J. F., Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clinical Cancer Research 1998 4 9 2245 2251 2-s2.0-0031694228 (Pubitemid 28415673)
60. Satyaswaroop P. G., Clarke C. L., Zaino R. J., Mortel R., Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Letters 1992 62 2 107 114 2-s2.0-0026525041 10.1016/0304-3835(92)90180-4
61. Zaino R. J., Satyaswaroop P. G., Mortel R., Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Research 1985 45 2 539 541 2-s2.0-0021959835 (Pubitemid 15161041)
62. Tisell L. E., Salander H., Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats. Acta Endocrinologica 1975 78 2 316 324 2-s2.0-0016466416
63. Pazol K., Wilson M. E., Wallen K., Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2998 3006 2-s2.0-2942696429 10.1210/jc.2003-032086 (Pubitemid 38766400)
64. Poulin R., Baker D., Poirier D., Labrie F., Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Research and Treatment 1989 13 2 161 172 2-s2.0-0024574381 (Pubitemid 19120108)
65. Birrell S. N., Hall R. E., Tilley W. D., Role of the androgen receptor in human breast cancer. Journal of Mammary Gland Biology and Neoplasia 1998 3 1 95 103 2-s2.0-0031597894 (Pubitemid 128513223)
66. Buchanan G., Birrell S. N., Peters A. A., Bianco-Miotto T., Ramsay K., Cops E. J., Yang M., Harris J. M., Simila H. A., Moore N. L., Bentel J. M., Ricciardelli C., Horsfall D. J., Butler L. M., Tilley W. D., Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research 2005 65 18 8487 8496 2-s2.0-24944465957 10.1158/0008-5472.CAN-04-3077 (Pubitemid 41330617)
67. Ettinger B., Golditch I. M., Medroxyprogesterone acetate for the evaluation of hypertestosteronism in hirsute women. Fertility and Sterility 1977 28 12 1285 1288 2-s2.0-0017589560 (Pubitemid 8257792)
68. Correa De Oliveira R. F., Novaes L. P., Lima M. B., A new treatment for hirsutism. Annals of Internal Medicine 1975 83 6 817 819 2-s2.0-0016829855
69. Richman R. A., Underwood L. E., French F. S., Van Wyk J. J., Adverse effects of large doses ofmedroxyprogesterone (MPA) in idiopathic isosexual precocity. The Journal of Pediatrics 1971 79 6 963 971 2-s2.0-0015174948
70. Edwards D. P., Wardell S. E., Boonyaratanakornkit V., Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. Journal of Steroid Biochemistry and Molecular Biology 2002 83 1-5 173 186 2-s2.0-0038657687 10.1016/S0960-0760(02)00265-0 (Pubitemid 37040654)
71. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., Chambon P., Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO Journal 1990 9 5 1603 1614 2-s2.0-0025239785
72. Tsai M. J., O'Malley B. W., Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 1994 63 451 486 2-s2.0-0028283503 (Pubitemid 24218640)
73. Cheung J., Smith D. F., Molecular chaperone interactions with steroid receptors: an update. Molecular Endocrinology 2000 14 7 939 946 2-s2.0-0034463399 10.1210/me.14.7.939 (Pubitemid 32250512)
74. Hammes S. R., Levin E. R., Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 2011 152 12 4489 4495
75. Lindet C., Révillion F., Lhotellier V., Hornez L., Peyrat J. P., Bonneterre J., Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers. The International Journal of Biological Markers 2012 27 2 e111 e117
76. Wen D. X., Xu Y. F., Mais D. E., Goldman M. E., McDonnell D. P., The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Molecular and Cellular Biology 1994 14 12 8356 8364 2-s2.0-0028033988 (Pubitemid 24373584)
77. Vegeto E., Shahbaz M. M., Wen D. X., Goldman M. E., O'Malley B. W., McDonnell D. P., Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Molecular Endocrinology 1993 7 10 1244 1255 2-s2.0-0027427216 10.1210/me.7.10.1244 (Pubitemid 23319107)
78. Edwards D. P., Regulation of signal transduction pathways by estrogen and progesterone. Annual Review of Physiology 2005 67 335 376 2-s2.0-15744393640 10.1146/annurev.physiol.67.040403.120151 (Pubitemid 40409510)
79. Boonyaratanakornkit V., Scott M. P., Ribon V., Sherman L., Anderson S. M., Maller J. L., Miller W. T., Edwards D. P., Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Molecular Cell 2001 8 2 269 280 2-s2.0-0034852802 10.1016/S1097-2765(01)00304-5 (Pubitemid 32831545)
80. Castoria G., Barone M. V., Di Domenico M., Bilancio A., Ametrano D., Migliaccio A., Auricchio F., Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO Journal 1999 18 9 2500 2510 2-s2.0-0033522392 10.1093/emboj/18.9.2500 (Pubitemid 29213282)
81. Li Z., Watkins E. B., Liu H., Chittiboyina A. G., Carvalho P. B., Avery M. A., 1,3-Diaxially substituted trans-decalins: potential nonsteroidal human progesterone receptor inhibitors. Journal of Organic Chemistry 2008 73 19 7764 7767 2-s2.0-53049091621 10.1021/jo800947m
82. Skildum A., Faivre E., Lange C. A., Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Molecular Endocrinology 2005 19 2 327 339 2-s2.0-13544276888 10.1210/me.2004-0306 (Pubitemid 40223458)
83. Faivre E. J., Lange C. A., Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Molecular and Cellular Biology 2007 27 2 466 480 2-s2.0-33846138978 10.1128/MCB.01539-06 (Pubitemid 46080117)
84. Ballaré C., Uhrig M., Bechtold T., Sancho E., Di Domenico M., Migliaccio A., Auricchio F., Beato M., Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Molecular and Cellular Biology 2003 23 6 1994 2008 2-s2.0-0037371863 10.1128/MCB.23.6.1994-2008.2003 (Pubitemid 36278811)
85. Carnevale R. P., Proietti C. J., Salatino M., Urtreger A., Peluffo G., Edwards D. P., Boonyaratanakornkit V., Charreau E. H., De Kier Joffé E. B., Schillaci R., Elizalde P. V., Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Molecular Endocrinology 2007 21 6 1335 1358 2-s2.0-34250883219 10.1210/me.2006-0304 (Pubitemid 46984741)
86. Proietti C., Salatino M., Rosemblit C., Carnevale R., Pecci A., Kornblihtt A. R., Molinolo A. A., Frahm I., Charreau E. H., Schillaci R., Elizalde P. V., Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Molecular and Cellular Biology 2005 25 12 4826 4840 2-s2.0-20344391678 10.1128/MCB.25.12.4826-4840.2005 (Pubitemid 40781085)
87. Llovet J. M., Di Bisceglie A. M., Bruix J., Kramer B. S., Lencioni R., Zhu A. X., Sherman M., Schwartz M., Lotze M., Talwalkar J., Gores G. J., Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 2008 100 10 698 711 2-s2.0-44449085884 10.1093/jnci/djn134
88. Itagaki T., Shimizu I., Cheng X., Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 2005 54 12 1782 1789 2-s2.0-54349108207 10.1136/gut.2004.053728corr1 (Pubitemid 41697679)
89. Boonyaratanakornkit V., Bi Y., Rudd M., Edwards D. P., The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 2008 73 9-10 922 928 2-s2.0-44549083120 10.1016/j.steroids.2008.01.010
90. Ito Y., Kawakatsu H., Takeda T., Sakon M., Nagano H., Sakai T., Miyoshi E., Noda K., Tsujimoto M., Wakasa K. I., Monden M., Matsuura N., Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. Journal of Hepatology 2001 35 1 68 73 2-s2.0-0034939717 10.1016/S0168-8278(01)00077-0 (Pubitemid 32646226)
91. Falkenstein E., Heck M., Gerdes D., Grube D., Christ M., Weigel M., Buddhikot M., Meizel S., Wehling M., Specific progesterone binding to a membrane protein and related nongenomic effects on Ca2+-fluxes in sperm. Endocrinology 1999 140 12 5999 6002 2-s2.0-0033305449 (Pubitemid 30645392)
92. Peluso J. J., Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 2011 76 9 903 909 2-s2.0-79959892278 10.1016/j.steroids.2011. 02.011
93. Wheeler K. T., Wang L. M., Wallen C. A., Childers S. R., Cline J. M., Keng P. C., Mach R. H., Sigma-2 receptors as a biomarker of proliferation in solid tumours. British Journal of Cancer 2000 82 6 1223 1232 2-s2.0-0034010937 (Pubitemid 30128883)
94. Peluso J. J., Romak J., Liu X., Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008 149 2 534 543 2-s2.0-38549114147 10.1210/en.2007-1050 (Pubitemid 351159360)
95. Rohe H. J., Ahmed I. S., Twist K. E., Craven R. J., PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacology and Therapeutics 2009 121 1 14 19 2-s2.0-57749085501 10.1016/j.pharmthera.2008.09. 006
96. Toyoda Y., Endo S., Tsuneyama K., Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicological Sciences 2012 126 1 16 27
97. Lundgren S., Lonning P. E., Utaaker E., Aakvaag A., Kvinnsland S., Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-I. General findings. Journal of Steroid Biochemistry 1990 36 1-2 99 104 2-s2.0-0025315578 10.1016/0022-4731(90)90118-C (Pubitemid 20213572)
98. Geller J., Albert J., Geller S., Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. Prostate 1982 3 1 11 15 2-s2.0-0020057235 (Pubitemid 12122497)
99. Blumenschein G. R., The role of progestins in the treatment of breast cancer. Seminars in Oncology 1983 10 4, supplement 7 10 2-s2.0-0021080364 (Pubitemid 14156496)
100. Eil C., Edelson S. K., The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. Journal of Clinical Endocrinology and Metabolism 1984 59 1 51 55 2-s2.0-0021220629 (Pubitemid 14087524)
101. Luthy I. A., Begin D. J., Labrie F., Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. Journal of Steroid Biochemistry 1988 31 5 845 852 2-s2.0-0024237507 (Pubitemid 19006901)
102. Poyet P., Labrie F., Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Molecular and Cellular Endocrinology 1985 42 3 283 288 2-s2.0-0022258792 10.1016/0303-7207(85)90059-0 (Pubitemid 15012062)
103. Farrar D. J., Megestrol acetate: promises and pitfalls. AIDS Patient Care and STDs 1999 13 3 149 152 2-s2.0-0032943141 (Pubitemid 29155982)
104. Martoni A. A., Bernardi A., Quercia S., Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer. Anticancer Research 2006 26 5 B 3739 3744 2-s2.0-33750694939 (Pubitemid 44701452)
105. Schindler A. E., Campagnoli C., Druckmann R., Huber J., Pasqualini J. R., Schweppe K. W., Thijssen J. H. H., Classification and pharmacology of progestins. Maturitas 2003 46 1, supplement S7 S16 2-s2.0-0344737047 10.1016/j.maturitas.2003.09.014 (Pubitemid 37506058)
106. Kalra M., Mayes J., Assefa S., Kaul A. K., Kaul R., Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World Journal of Gastroenterology 2008 14 39 5945 5961 2-s2.0-59849099695 10.3748/wjg.14.5945